ribavirin
proven
effect
sever
virus
clinic
set
multitud
virus
vitro
five
differ
propos
mechan
action
recent
advanc
begun
discern
hierarchi
antivir
effect
play
depend
viru
host
condit
scrutini
studi
reveal
mani
virus
antivir
mechan
may
differ
depend
cell
type
vitro
vivo
analys
thu
requir
accur
identifi
mechan
optim
determin
clinic
treatment
recent
year
grow
number
ribavirin
resist
sensit
variant
identifi
variant
inform
specif
mechan
ribavirin
enfeebl
viru
also
tool
identifi
new
antivir
compound
ribavirin
rbv
synthet
guanosin
analog
broadspectrum
antivir
activ
clinic
effect
sever
virus
respiratori
syncyti
viru
sever
hemorrhag
fever
virus
hcv
combin
pegyl
interferona
moreov
effect
larg
panel
rna
dna
viru
infect
vitro
summar
tabl
nevertheless
mechan
action
ribavirin
still
scrutini
appear
differ
depend
viru
question
cell
line
use
studi
propos
mechan
two
indirectli
affect
viru
one
base
inhibit
inosin
monophosph
dehydrogenas
impdh
monophosph
lead
deplet
intracellular
gtp
pool
second
one
propos
postul
unphosphoryl
rbv
immunomodulatori
effect
antivir
cellular
respons
enhanc
thelper
type
type
respons
upregul
interferonstimul
respons
element
addit
three
direct
mechan
propos
first
inhibit
viral
rna
depend
rna
polymeras
rdrp
direct
interact
triphosph
second
interf
rna
cap
activ
although
extens
studi
demonstr
recent
year
third
increas
viral
mutat
rate
misincorpor
rbv
genom
lead
popul
extinct
review
recent
studi
rbv
effect
viral
replic
propag
vitro
vivo
molecular
basi
ribavirin
resist
sever
recent
studi
continu
explor
rbv
antivir
therapeut
treatment
differ
virus
recent
year
studi
focus
whether
rbv
directli
inhibit
rdrp
mutagen
genom
inhibit
impdh
combin
three
inhibit
rna
synthesi
observ
influenza
viru
polymeras
cell
treat
either
rbv
methotrex
inhibitor
purin
synthesi
decreas
intracellular
concentr
purin
case
loss
polymeras
activ
low
concentr
nucleotid
consid
culprit
hepat
e
viru
hev
replic
vitro
rbv
antivir
effect
two
impdh
inhibitor
mycophenol
acid
mpa
eicar
neutral
addit
guanosin
hev
replic
appear
inhibit
deplet
gtp
pool
inhibit
impdh
similarli
rbv
effect
hcv
seemingli
act
inhibit
impdh
sinc
addit
guanosin
negat
effect
hcv
rna
synthesi
suppress
impdhknockdown
cell
mutagen
activ
observ
hcv
infect
hepatoma
cell
result
contradict
later
obtain
cell
line
mutagen
activ
inde
observ
mutagenesi
mediat
deplet
gtp
level
sinc
addit
guanosin
significantli
alter
effect
deplet
gtp
mpa
also
mutagen
effect
suggest
direct
incorpor
rbv
hcv
genom
underli
mechan
nevertheless
studi
uncov
ntp
imbal
result
rbv
treatment
might
contribut
inhibit
rna
synthesi
mechan
relat
independ
mutagenesi
case
arenavirus
appear
rbv
multipl
effect
lymphocyt
choriomening
viru
lmcv
inhibit
like
mediat
decreas
gtp
level
caus
monophosph
inhibit
impdh
mutagen
activ
also
occur
incorpor
rbv
nascent
rna
final
direct
interact
viral
polymeras
suggest
case
hantaan
viru
htnv
vero
cell
treat
rbv
reduct
viral
genom
rna
infecti
particl
observ
associ
signific
reduct
gtp
level
would
expect
impdh
inhibit
primari
antivir
effect
rather
observ
increas
triphosph
support
direct
interact
rdrp
mechan
inhibit
like
virus
ribavirin
inde
pleiotrop
effect
may
differ
import
depend
concentr
cell
type
studi
highlight
possibl
contradict
result
due
choic
cell
line
question
extent
cell
line
repres
vivo
set
although
studi
ribavirin
antivir
drug
justli
focus
effect
viru
import
set
recent
studi
examin
host
cell
may
react
rbv
exposur
one
studi
reveal
dramat
variat
accumul
rbv
seven
differ
cell
line
author
show
uptak
rbv
equilibr
nucleosid
transport
similar
cell
type
level
intracellular
rbv
seemingli
resist
cell
like
vero
notic
lower
hela
importantli
profil
correl
lack
antivir
efficaci
vsv
sendai
viru
author
conclud
abil
given
cell
type
metabol
rbv
may
determin
rbv
antivir
effect
play
case
hcovemc
coronaviru
lack
sensit
rbv
also
observ
vero
cell
cell
respons
interestingli
rbvrespons
cell
passag
presenc
ribavirin
develop
resist
phenotyp
correl
reduc
rbv
uptak
andor
process
furthermor
reduc
uptak
develop
pbmc
healthi
donor
treat
week
rbv
pbmc
hcvinfect
patient
receiv
ribavirininterferon
combin
therapi
ribavirin
drug
activ
mani
virus
multipl
effect
viru
replic
propag
molecular
basi
ribavirin
resist
ribavirin
proven
effect
sever
virus
clinic
set
multitud
virus
vitro
five
differ
propos
mechan
action
recent
advanc
begun
discern
hierarchi
antivir
effect
play
depend
viru
host
condit
scrutini
studi
reveal
mani
virus
antivir
mechan
may
differ
depend
cell
type
vitro
vivo
analys
thu
requir
accur
identifi
mechan
optim
determin
clinic
treatment
recent
year
grow
number
ribavirin
resist
sensit
variant
identifi
variant
inform
specif
mechan
ribavirin
enfeebl
viru
also
tool
identifi
new
antivir
compound
ribavirin
rbv
synthet
guanosin
analog
broadspectrum
antivir
activ
clinic
effect
sever
virus
respiratori
syncyti
viru
sever
hemorrhag
fever
virus
hcv
combin
pegyl
interferona
moreov
effect
larg
panel
rna
dna
viru
infect
vitro
summar
tabl
nevertheless
mechan
action
ribavirin
still
scrutini
appear
differ
depend
viru
question
cell
line
use
studi
propos
mechan
two
indirectli
affect
viru
one
base
inhibit
inosin
monophosph
dehydrogenas
impdh
monophosph
lead
deplet
intracellular
gtp
pool
second
one
propos
postul
unphosphoryl
rbv
immunomodulatori
effect
antivir
cellular
respons
enhanc
thelper
type
type
respons
upregul
interferonstimul
respons
element
addit
three
direct
mechan
propos
first
inhibit
viral
rna
depend
rna
polymeras
rdrp
direct
interact
triphosph
second
interf
rna
cap
activ
although
extens
studi
demonstr
recent
year
third
increas
viral
mutat
rate
misincorpor
rbv
genom
lead
popul
extinct
review
recent
studi
rbv
effect
viral
replic
propag
vitro
vivo
molecular
basi
ribavirin
resist
sever
recent
studi
continu
explor
rbv
antivir
therapeut
treatment
differ
virus
recent
year
studi
focus
whether
rbv
directli
inhibit
rdrp
mutagen
genom
inhibit
impdh
combin
three
inhibit
rna
synthesi
observ
influenza
viru
polymeras
cell
treat
either
rbv
methotrex
inhibitor
purin
synthesi
decreas
intracellular
concentr
purin
case
loss
polymeras
activ
low
concentr
nucleotid
consid
culprit
hepat
e
viru
hev
replic
vitro
rbv
antivir
effect
two
impdh
inhibitor
mycophenol
acid
mpa
eicar
neutral
addit
guanosin
hev
replic
appear
inhibit
deplet
gtp
pool
inhibit
impdh
similarli
rbv
effect
hcv
seemingli
act
inhibit
impdh
sinc
addit
guanosin
negat
effect
hcv
rna
synthesi
suppress
impdhknockdown
cell
mutagen
activ
observ
hcv
infect
hepatoma
cell
result
contradict
later
obtain
cell
line
mutagen
activ
inde
observ
mutagenesi
mediat
deplet
gtp
level
sinc
addit
guanosin
significantli
alter
effect
deplet
gtp
mpa
also
mutagen
effect
suggest
direct
incorpor
rbv
hcv
genom
underli
mechan
nevertheless
studi
uncov
ntp
imbal
result
rbv
treatment
might
contribut
inhibit
rna
synthesi
mechan
relat
independ
mutagenesi
case
arenavirus
appear
rbv
multipl
effect
lymphocyt
choriomening
viru
lmcv
inhibit
like
mediat
decreas
gtp
level
caus
monophosph
inhibit
impdh
mutagen
activ
also
occur
incorpor
rbv
nascent
rna
final
direct
interact
viral
polymeras
suggest
case
hantaan
viru
htnv
vero
cell
treat
rbv
reduct
viral
genom
rna
infecti
particl
observ
associ
signific
reduct
gtp
level
would
expect
impdh
inhibit
primari
antivir
effect
rather
observ
increas
triphosph
support
direct
interact
rdrp
mechan
inhibit
like
virus
ribavirin
inde
pleiotrop
effect
may
differ
import
depend
concentr
cell
type
studi
highlight
possibl
contradict
result
due
choic
cell
line
question
extent
cell
line
repres
vivo
set
although
studi
ribavirin
antivir
drug
justli
focus
effect
viru
import
set
recent
studi
examin
host
cell
may
react
rbv
exposur
one
studi
reveal
dramat
variat
accumul
rbv
seven
differ
cell
line
author
show
uptak
rbv
equilibr
nucleosid
transport
similar
cell
type
level
intracellular
rbv
seemingli
resist
cell
like
vero
notic
lower
hela
importantli
profil
correl
lack
antivir
efficaci
vsv
sendai
viru
author
conclud
abil
given
cell
type
metabol
rbv
may
determin
rbv
antivir
effect
play
case
hcovemc
coronaviru
lack
sensit
rbv
also
observ
vero
cell
cell
respons
interestingli
rbvrespons
cell
passag
presenc
ribavirin
develop
resist
phenotyp
correl
reduc
rbv
uptak
andor
process
furthermor
reduc
uptak
develop
pbmc
healthi
donor
treat
week
rbv
pbmc
hcvinfect
patient
receiv
ribavirininterferon
combin
therapi
trend
recent
year
explor
mutagenesi
primari
antivir
effect
rna
virus
lethal
mutagenesi
serious
consid
valid
antivir
approach
howev
trend
base
biochem
tissu
cultur
studi
futur
effort
like
focu
determin
whether
mutagenesi
occur
vivo
optim
activ
therapeut
context
although
rbv
enough
antivir
benefit
virus
warrant
clinic
use
despit
vivo
mechan
remain
unclear
possibl
ribavirin
antivir
activ
resist
beaucourt
vignuzzi
tabl
broadspectrum
antivir
activ
ribavirin
adapt
updat
lack
knowledg
result
suboptim
target
efficaci
standard
treatment
nongenotyp
hcv
recent
emerg
small
molecul
direct
act
antivir
combin
pegyl
interferona
rbv
although
neither
drug
seem
direct
effect
viru
regard
rbv
enhanc
ifng
respons
natur
killer
cell
ifna
stimul
assess
rbv
physiolog
level
monoinfect
hiv
coinfect
patient
one
studi
correl
lower
respons
rate
hivinfect
patient
lower
rbv
bioavail
interestingli
combin
therapi
surprisingli
effect
dissemin
human
papillomaviru
infect
patient
previous
undergon
treatment
psoriasi
hivhcv
coinfect
patient
well
patient
acquir
aplast
anemia
hcv
infect
patient
undergo
rbv
monotherapi
moder
transient
antivir
effect
observ
lack
clear
direct
inhibitorymutagen
effect
rbv
hcv
vivo
thought
question
physiolog
concentr
drug
issu
sampl
wrong
compart
blood
versu
liver
howev
recent
studi
rbv
found
induc
significantli
gtoa
ctou
transit
genet
signatur
indic
ribavirininduc
mutagenesi
whether
effect
suffici
strong
benefit
yet
determin
clinic
infect
rbv
monotherapi
remain
treatment
choic
exampl
transplant
patient
treat
hepat
e
infect
rbv
therapi
ensur
sustain
virolog
respons
patient
firstlin
second
prolong
therapi
also
welltoler
option
treat
respiratori
syncyti
viru
infect
immunocompromis
patient
antivir
treatment
crimeancongo
hemorrhag
fever
appear
benefici
administr
earli
decreas
sever
fatal
rate
preliminari
studi
combin
treatment
also
shown
effect
rhinoviru
rv
patient
hypogammaglobulinemia
suscept
rv
infect
explor
intervent
strategi
recent
identifi
b
coronaviru
isol
treatment
rhesu
macaqu
rbv
alon
reduc
viru
replic
combin
treatment
even
effect
permit
lower
dose
line
clinic
use
final
rbv
shown
protect
potenti
lethal
hantaviru
pulmonari
syndrom
intranas
exposur
hamster
and
viru
presenc
live
viru
reduc
abolish
serum
number
rbv
resist
variant
either
gener
isol
within
picornavirida
famili
map
rdrp
mani
resist
accompani
increas
fidel
tabl
first
ribavirinresist
polioviru
variant
contain
rdrp
led
gener
four
rbvresist
variant
amino
acid
posit
l
v
variant
resist
effect
sever
mutagen
increas
replic
fidel
mutat
similar
polioviru
gener
human
enteroviru
antivir
resist
tabl
ribavirin
resist
sensit
variant
unless
otherwis
indic
mutat
appear
rdrp
mechan
resist
sensit
indic
known
confer
resist
rbv
increas
fidel
recent
fmdv
mutagenresist
rdrp
variant
isol
use
anoth
mutagen
compound
variant
also
resist
rbv
third
mutagen
azc
would
expect
high
fidel
virus
natur
occur
rdrp
variant
coxsacki
viru
also
resist
three
mutagen
increas
fidel
yet
anoth
high
fidel
rdrp
variant
select
rbv
passag
within
togavirida
famili
polymeras
mutant
chikungunya
viru
isol
use
mutagen
passag
rbv
demonstr
higher
replic
fidel
hcv
ribavirin
resist
mutat
protein
first
describ
use
replicon
system
recent
resist
popul
isol
serial
passag
viru
rbv
present
dozen
mutat
throughout
genom
could
respons
includ
rdrp
precis
determin
known
later
studi
confirm
popul
also
resist
support
increas
fidel
mechan
behind
resist
case
howev
precis
mechan
resist
remain
unclear
fidel
may
may
involv
orthomyxovirida
influenza
viru
variant
catalyt
subunit
viral
replicas
isol
display
higher
activ
wild
type
viru
presenc
rbv
well
inhibitor
purin
biosynthesi
methotrex
author
suggest
residu
involv
nucleotid
recognit
whether
resist
result
increas
fidel
increas
process
remain
determin
recent
anoth
ribavirinresist
fmdv
polymeras
variant
mutant
carri
four
rdrp
amino
acid
substitut
call
damm
isol
toler
azc
treatment
variant
rbvspecif
resist
profil
similar
first
rbvresist
fmdv
polymeras
variant
suggest
increas
fidel
basi
resist
wherea
rbv
resist
variant
wide
report
readili
isol
mutagen
screen
rbv
sensit
variant
also
recent
isol
gener
dozen
variant
differ
residu
posit
coxsacki
viru
polymeras
sever
variant
rdrp
residu
chikungunya
sindbi
viru
sensit
base
analog
mutagen
reduc
polymeras
fidel
confirm
mutagen
affect
rbv
rna
virus
case
coronavirus
cov
hypersensit
exonmut
gener
interest
data
recent
year
given
coronavirus
largest
rna
genom
would
expectedli
hypersensit
rna
mutagen
rbv
howev
seem
case
follow
discoveri
potenti
exoribonucleas
exon
proofread
activ
hypothes
delet
activ
would
result
rbv
sensit
hypothesi
valid
use
murin
hepat
viru
mhv
sarscov
exonmut
treat
rbv
last
year
vitro
studi
rbv
sought
identifi
mechan
contribut
observ
antivir
effect
appear
mani
case
pleiotrop
compound
simpli
true
pleiotrop
natur
signific
recent
advanc
complic
toward
goal
variabl
observ
cell
type
tissu
rbv
uptak
metabol
could
impact
efficaci
drug
administ
one
mechan
mind
anoth
mechan
ultim
work
futur
research
requir
better
valid
mechan
depend
cell
system
use
especi
case
hcv
import
goal
determin
ribavirin
treatment
affect
viru
vivo
properli
tailor
treatment
identifi
altern
compound
similar
effect
current
use
anim
model
bridg
laboratori
clinic
studi
rel
scarc
addit
recent
isol
rbvresist
sensit
variant
repres
new
tool
improv
efficaci
current
mutagen
compound
identifi
new
compound
previous
unknown
antivir
mutagen
activ
exampl
isol
coxsacki
viru
rdrp
variant
two
independ
screen
rna
mutagen
amilorid
resist
led
discoveri
previous
unknown
indirect
mutagen
activ
latter
class
compound
especi
relev
era
combin
therapi
drug
differ
mode
action
need
whether
inhibitor
mutagen
